Acute asthma intervention: Insights from the STAY study

Slides:

Advertisements

Similar presentations

Control of immunopathology during chikungunya virus infection Caroline Petitdemange, PhD, Nadia Wauquier, PhD, Vincent Vieillard, PhD Journal of Allergy.

Advertisements

D-dimer: A biomarker for antihistamine-resistant chronic urticaria

Comparison of adjustable- and fixed-dose budesonide/formoterol pressurized metered- dose inhaler and fixed-dose fluticasone propionate/salmeterol dry powder.

Mark S. La Shell, MD, Christopher W. Calabria, MD, James M. Quinn, MD

The Inhaled Steroid Treatment As Regular Therapy in Early Asthma (START) study 5- year follow-up: Effectiveness of early intervention with budesonide in.

Megan E. Jensen, PhD, Morton J

Allergen immunotherapy: A practice parameter third update

Risk of an asthma exacerbation after bariatric surgery in adults

Pharmacologic rationale for treating allergic and nonallergic rhinitis

Acute asthma, prognosis, and treatment

Santa Jeremy Ono, BA, PhD, Mark B. Abelson, MD

Ophthalmologic findings in children with asthma receiving inhaled budesonide Anna Pelkonen, MD, PhD, Osmo Kari, MD, PhD, Olof Selroos, MD, PhD, Kurt Nikander,

Dorothy M. Ryan, MD, Stephen J. Fowler, MD, Robert M. Niven, MD

Is 9 more than 2 also in allergic airway inflammation?

Airway inflammation in patients with asthma with high-fixed or low-fixed plus as-needed budesonide/formoterol Ian D. Pavord, DM, FRCP, Peter K. Jeffery,

Eric D. Bateman, MD, Helen K

Hospitalization rates and prognosis of patients with anaphylactic shock in Denmark from 1995 through 2012 Anni Nørgaard Jeppesen, MD, Christian Fynbo.

NAEPP Expert Panel Report

Quantifying the proportion of severe asthma exacerbations attributable to inhaled corticosteroid nonadherence L. Keoki Williams, MD, MPH, Edward L. Peterson,

Katherine A. Vierk, MPH, Kathleen M. Koehler, PhD, MPH, Sara B

Excessive gestational weight gain in first trimester is a risk factor for exacerbation of asthma during pregnancy: A prospective study of 1283 pregnancies

The risk of asthma exacerbation after stopping low-dose inhaled corticosteroids: A systematic review and meta-analysis of randomized controlled trials

Demographic and clinical characteristics of children and adolescents with severe or difficult-to-treat asthma Bradley E. Chipps, MD, Stanley J. Szefler,

Physician needs in health informatics: Just ask the docs

Tari Haahtela, MD, PhD, Klaus Tamminen, MD, Tuomo Kava, MD, PhD, L

Nonadherence to Asthma Treatment: Getting Unstuck

Peter M. Wolfgram, MD, David B. Allen, MD

Asthma symptom re-emergence after omalizumab withdrawal correlates well with increasing IgE and decreasing pharmacokinetic concentrations Raymond G.

Etiology of asthma exacerbations

Are the concepts of induction of remission and treatment of subclinical inflammation in atopic dermatitis clinically useful? Ting Seng Tang, MBBS, Thomas.

Jewlya Lynn, PhD, Sophie Oppenheimer, MS, MPH, Lorena Zimmer, MA

Approaches to the diagnosis and management of patients with a history of nonsteroidal anti-inflammatory drug–related urticaria and angioedema Marek L.

Short- and long-term efficacy of prednisolone for first acute rhinovirus-induced wheezing episode Tuomas Jartti, MD, Riitta Nieminen, BM, Tytti Vuorinen,

Paul M. O’Byrne, MB, FRCPI, FRCP(C)a, Soren Pedersen, MD, PhDb

Comparison of US emergency department acute asthma care quality: and

Time for a paradigm shift in asthma treatment: From relieving bronchospasm to controlling systemic inflammation Leif Bjermer, MD Journal of Allergy.

Food allergy: A review and update on epidemiology, pathogenesis, diagnosis, prevention, and management Scott H. Sicherer, MD, Hugh A. Sampson, MD Journal.

Interactions between breast-feeding, specific parental atopy, and sex on development of asthma and atopy Piush J. Mandhane, MD, Justina M. Greene, Dip.

A cluster-randomized trial shows telephone peer coaching for parents reduces children's asthma morbidity Jane M. Garbutt, MB, ChB, Yan Yan, MD, PhD,

Claus Bachert, MD, PhD, Cezmi A. Akdis, MD

Effect of ingested H1 antihistamines on methacholine challenge

What is an “eosinophilic phenotype” of asthma?

Medication use in children with asthma in Finland from 1995 to 2006

H. William Kelly, PharmD Journal of Allergy and Clinical Immunology

Cockroach allergens: Coping with challenging complexity

Autophagy: Nobel Prize 2016 and allergy and asthma research

News & Notes Journal of Allergy and Clinical Immunology

Food allergy: Epidemiology, pathogenesis, diagnosis, and treatment

Advances in the approach to the patient with food allergy

Diagnosis and management of early asthma in preschool-aged children

Mark S. La Shell, MD, Christopher W. Calabria, MD, James M. Quinn, MD

Comparison of adjustable- and fixed-dose budesonide/formoterol pressurized metered- dose inhaler and fixed-dose fluticasone propionate/salmeterol dry powder.

Development and validation of a novel risk score for asthma exacerbations: The risk score for exacerbations Eric D. Bateman, MD, Roland Buhl, MD, Paul.

Therapeutic strategies to reduce asthma exacerbations

Protection by budesonide and fluticasone on allergen-induced airway responses after discontinuation of therapy Padmaja Subbarao, MD, MSc, Sandra C. Dorman,

Risk of oral food challenges

Time trends in Australian hospital anaphylaxis admissions in to

Nitric oxide as a clinical guide for asthma management

Measles and immunomodulation

Severity assessment in asthma: An evolving concept

Managing asthma exacerbations in the emergency department: Summary of the National Asthma Education and Prevention Program Expert Panel Report 3 guidelines.

Macrolide antibiotics and asthma treatment

Neil W. Johnston, MSc, Sebastian L. Johnston, MD, PhD, Joanne M

Budesonide Inhalation Suspension Versus Montelukast in Children Aged 2 to 4 Years with Mild Persistent Asthma Stanley J. Szefler, MD, Lars-Goran Carlsson,

Asthma: The past, future, environment, and costs

Advances in pediatric asthma in 2007

Negative affect, medication adherence, and asthma control in children

Natural history of cow’s milk allergy

Primary prevention of asthma and allergy

Modeling asthma exacerbations through lung function in children

Presentation transcript:

Acute asthma intervention: Insights from the STAY study Paul M. O'Byrne, MB, FRCP(C) Journal of Allergy and Clinical Immunology Volume 119, Issue 6, Pages 1332-1336 (June 2007) DOI: 10.1016/j.jaci.2007.03.007 Copyright © 2007 American Academy of Allergy, Asthma & Immunology Terms and Conditions

Fig 1 All severe asthma exacerbations requiring medical intervention in the STAY study. Each exacerbation is represented by a line, and the length of the line represents the duration of the exacerbation. Patients receiving budesonide (Bud) 800 μg/d with terbutaline as reliever are in the upper panel; patients receiving budesonide/formoterol (Form) 200/6 μg/d with terbutaline as reliever are in the middle panel; and patients receiving budesonide/formoterol 200/6 μg/d with budesonide/formoterol as reliever are in the lower panel. Budesonide/formoterol as maintenance and reliever significantly reduced the number of severe exacerbations compared with the other 2 groups. Journal of Allergy and Clinical Immunology 2007 119, 1332-1336DOI: (10.1016/j.jaci.2007.03.007) Copyright © 2007 American Academy of Allergy, Asthma & Immunology Terms and Conditions

Fig 2 Number of severe exacerbations in the STAY study during 1 year of treatment with budesonide (Bud) 800 μg/d with terbutaline as rescue inhaler, or budesonide/formoterol 200/6 μg/d with terbutaline as rescue inhaler, or budesonide/formoterol 200/6 μg/d with budesonide/formoterol as rescue inhaler (left panel). Also shown are the number of exacerbations defined by the fall in PEF criterion (>30% from baseline for 2 consecutive days), or by the number of oral corticosteroid courses decided by the managing physician, or by a hospitalization of emergency department (ED) visit. Budesonide/formoterol used both as maintenance and reliever significantly reduced the number of exacerbations in all categories. Data from reference 13. Journal of Allergy and Clinical Immunology 2007 119, 1332-1336DOI: (10.1016/j.jaci.2007.03.007) Copyright © 2007 American Academy of Allergy, Asthma & Immunology Terms and Conditions

Fig 3 All severe asthma exacerbations requiring medical intervention in the children (age 4-11 years) in the STAY study. Each exacerbation is represented by a line, and the length of the line represents the duration of the exacerbation. Patients receiving budesonide (Bud) 400 μg/d with terbutaline as reliever are in the upper panel; patients receiving budesonide/formoterol (Form) 100/6 μg/d with terbutaline as reliever are in the middle panel; and patients receiving budesonide/formoterol 100/6 μg/d with budesonide/formoterol as reliever are in the lower panel. Budesonide/formoterol as maintenance and reliever significantly reduced the number of severe exacerbations compared with the other 2 groups. Journal of Allergy and Clinical Immunology 2007 119, 1332-1336DOI: (10.1016/j.jaci.2007.03.007) Copyright © 2007 American Academy of Allergy, Asthma & Immunology Terms and Conditions